Drug
Alpha-0261
Alpha-0261 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
not_yet_recruiting267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
NCT07744646
not_yet_recruitingphase_1
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
NCT07684560
completedphase_1
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
NCT07279636
Clinical Trials (3)
Showing 3 of 3 trials
NCT07744646Phase 1
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
NCT07684560Phase 1
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
NCT07279636Phase 1
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3